Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000859080 | SCV000285021 | benign | Familial hypercholesterolemia | 2024-12-04 | criteria provided, single submitter | clinical testing | |
Robarts Research Institute, |
RCV000225826 | SCV000484765 | benign | Hypercholesterolemia, familial, 1 | 2019-08-22 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000859080 | SCV001347004 | benign | Familial hypercholesterolemia | 2017-07-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001192513 | SCV001360707 | benign | not specified | 2019-03-04 | criteria provided, single submitter | clinical testing | Variant summary: The variant, LDLR c.1887C>T alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00052 in 277248 control chromosomes, predominantly at a frequency of 0.0042 within the Latino subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within Latino control individuals in the gnomAD database is approximately 3 fold of the estimated maximal expected allele frequency for a pathogenic variant in LDLR causing Familial Hypercholesterolemia phenotype (0.0013), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Latino origin. To our knowledge, no occurrence of c.1887C>T in individuals affected with Familial Hypercholesterolemia and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as benign. Based on the evidence outlined above, the variant was classified as benign. |
Ambry Genetics | RCV002408957 | SCV002723139 | likely benign | Cardiovascular phenotype | 2018-12-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
All of Us Research Program, |
RCV000225826 | SCV004818463 | benign | Hypercholesterolemia, familial, 1 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000859080 | SCV001453899 | benign | Familial hypercholesterolemia | 2020-06-25 | no assertion criteria provided | clinical testing |